SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis by Abdel-Fatah, TMA et al.
1 
 
A retrospective study of SPAG5 as a novel potentially actionable oncogene, 
prognostic biomarker and chemotherapy sensitivity predictor: - an integrated 
genomic, transcriptomic and protein analysis of 10,000 Breast Cancers  
Tarek M.A. Abdel-Fatah*1, Devika Agarwal2, Dong-Xu Liu3,4, Roslin Russell5, Oscar 
M Rueda5, Karen Liu3, Bing Xu3, Paul M. Moseley1, Andrew R. Green6, Prof Alan G. 
Pockley2, Prof Robert C. Rees2, Prof Carlos Caldas5, Prof Ian O. Ellis6, Prof Graham 
R. Ball*2, Prof Stephen Y.T. Chan*1 
1Clinical Oncology Department, Nottingham University Hospitals NHS Trust, 
Nottingham NG5 1PB, UK 
Professor S.Y.T. Chan DM, T.M.A. Abdel-Fatah PhD, P.M. Moseley BSc (Hons) 
2John van Geest Cancer Research Centre, School of Science and Technology, 
Nottingham Trent University, Clifton campus, Nottingham NG11 8NS, UK 
Professor R.C. Rees PhD, Professor A.G. Pockley PhD, Professor G.R. Ball PhD, D. 
Agarwal MSc 
3Liggins Institute, the University of Auckland, Auckland 1142, New Zealand 
D-X Liu PhD 
4The Institute of Genetics and Cytology, Northeast Normal University, Changchun, 
China 
D-X Liu PhD 
2 
 
5Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Robinson 
Way, Cambridge, UK 
Professor C. Caldas FMedSci, R. Russell PhD, O.M. Rueda PhD 
6Division of Cancer and Stem Cells, School of Medicine, University of Nottingham 
and Nottingham University Hospitals NHS Trust, Nottingham NG5 1PB, UK 
Professor I.O. Ellis FRCPath, A.R. Green PhD 
Running title: SPAG5 is novel actionable oncogene that predicts survival benefit 
from anthracycline therapy in breast cancer patients 
*Authors contributed equally  
  
3 
 
Corresponding author: 
Professor Stephen YT Chan  
Clinical Oncology Department 
Nottingham University Hospitals NHS Trust 
Nottingham NG5 1PB, U.K. 
Telephone: +44(0) 115 969 1169 
Fax: +44(0)115 962 8047 
E-Mail: steve.chan@nuh.nhs.uk  
The corresponding author confirms that he has full access to all the data in the study 
and has final responsibility for the decision to submit the manuscript for publication. 
  
4 
 
Research in context 
Evidence before this study 
Advances in molecular biology have generated a huge amount of data, which has 
then been used to generate multigene-profiles for guiding chemotherapy treatment.  
Unfortunately, almost all of these approaches face common issues, such as 
insufficiently high levels of evidence, the over-fitting of computational models, false 
discovery rates, and the lack of a potential biological mechanism to support their use 
as accurate predictors of the therapeutic response. Furthermore, they do not offer a 
significant improvement in predictive accuracy over the well-established pathological 
parameters or the cheaper, conventional immunohistochemistry approach, and may 
not be available for logistical or financial reasons.  Given that, the majority of the 
prognostic power of these assays comes from genes that are related to cell 
proliferation, a St Gallen International Expert Consensus recently recommended the 
use of proliferation markers/profiles when choosing the appropriate systemic-
treatment.  However, the best molecular-marker/test that should be used continues 
to be debated.   There was an urgent need to conduct a multi-dimensional clinical 
studies using multi-procedures and be validated in a large number of patients to 
identify a biomarker that could drive proliferation, and could be used clinically to 
stratify BC patients’ for the best outcome.  In addition there was a need to apply 
novel statistical approaches that are not limited by the linear functionality of 
conventional statistical approaches and can provide high sensitivity and specificity 
with excellent validity to prevent false discovery and over-fitting with sufficient power.  
Added value of this study 
To the best of our knowledge this is the first multi-dimensional study, with more than 
10,000 patients, to report on the clinicopathological utilities of SPAG5 in breast 
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cancer. Our findings suggest that: 1) Amplification/gain of the SPAG5 locus at 
Ch17q11·2 occurs in 10-20% of all breast cancers; 2) The SPAG5-gene copy 
number aberrations (CNAs) and its transcript and protein are associated with poor 
clinical outcome and adverse clinicopathological features, including TP53-mutation, 
PAM50-LumB, and PAM50-HER2; and 3) Both high expression of SPAG5 mRNA 
transcript and protein are independent predictors for response to chemotherapy.  
Implications of all the available evidence 
Our findings have the potential to introduce an accurate predictive biomarker for 
chemotherapy response, which would facilitate the tailoring of treatments to 
individual patients with breast cancer. This work may lead to the development of 
novel strategies for more effectively managing and treating a subtype of breast 
cancer.  
  
6 
 
Abstract =300 words 
Background: 
Although the use of proliferation markers/profiles has been recommended when 
choosing the appropriate systemic-treatment for breast cancer (BC), the best 
molecular-marker/test that should be used needs to be identified.   
Methods: 
To identify factors that drive proliferation and its associated features in BC an 
artificial neural network (ANN) based integrative data-mining methodology was 
applied to three cohorts [(Nottingham-discovery (ND), Uppsala and METABRIC 
(Molecular Taxonomy of Breast Cancer International Consortium)]. The most 
prominent genes in the resulting interactome-map were then identified.  Given that 
SPAG5 was associated with many features of proliferation, featured prominently in 
the interactome-map and has a fundamental role in mitotic-progression,, we 
hypothesized that it could be a better indicator of proliferation activity.  (BC). 
Subsequently to test if it could provide a more accurate guide for the delivery of 
systemic therapies in BC, we investigated the clinico-pathological utility of SPAG5: 
gene copy number aberrations (CNAs); mRNA and protein expression, in over 
10,000 BCs. Integrated analysis of SPAG5-gene CNAs, transcript and protein 
expression was conducted in the ND cohort (n=171) and validated in the METABRIC 
cohort (n=1980). In addition, the associations of SPAG5 CNAs, transcript and/or 
protein with BC specific survival (BCSS), disease free survival (DFS) and/or distant 
relapse free survival (DRFS) were analysed in multiple cohorts including Uppsala 
(n=249), METABRIC, three-untreated lymph node (LN) negative cohorts (n=684), a 
combined multicentre clinical data set (n=5439), Nottingham historical early-stage-
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primary BC  (Nottingham-HES-BC; n=1650), Nottingham oestrogen receptor (ER) 
negative BC (n=697), Nottingham anthracycline-Neoadjuvant-chemotherapy 
(Nottingham-AC-Neo-ACT; n=200), and MD Anderson Cancer Centre 
Taxane/anthracycline (MDACC-T/AC-Neo-ACT; n=508) cohorts. The association of 
SPAG5 transcript and protein expression with pathological response rate (pCR) were 
also tested in [MDACC-T/AC-Neo-ACT (n=508) and the phase II trial NCT00455533; 
n=253)] and [Nottingham-AC-Neo-ACT (n=200)] cohorts; respectively.   
Findings: 
SPAG5 gene gain/amplification at the Ch17q11·2 locus was found in 10.4% of BC 
(206/1980 (; METABRIC) and was reported in 19·4% of PAM50-HER2 (46/237) and 
17·8% of PAM50-LumB (87/488). SPAG5-CNA gain/amplification and high SPAG5-
transcript and SPAG5-protein were associated with increased risk of death from BC 
[Uppsala; (HR (CI 95%): 1·50 (1·18-1·92); p=0·00010, METABRIC; (HR (CI 95%): 
1·68 (1·40-2·01) p<0·0001), and Nottingham-HSE-BC; (HR (CI 95%): 1·68 (1·32-
2·12), p<0·0001); respectively]. Multivariable Cox regression models, including other 
validated-prognostic factors, (Uppsala: age, size, LN-stage, genomic grade index 
(GGI), ER, TP53 mutation and  MKi67; METABRIC: age, size, LN-stage,  histologic-
grade, ER, progesterone receptor (PR), human epidermal growth factor receptor 2 
(HER2), hormone-therapy, chemotherapy, interaction term of SPAG5 and both 
chemotherapy[y and hormonotherapy; Desmedt-untreated LN- cohort: ER, 
Nottingham prognostic index (NPI), 76-gene prognostic signature (Veridex) and  
Adjuvant-Online (AOL);  Nottingham-HES-BC: menopausal status, size, LN- stage,  
histologic-grade, ER, PR, HER2, ki67, hormone-therapy, chemotherapy, interaction 
term of SPAG5 and both chemotherapy[y and hormonotherapy), showed that high 
SPAG5-transcript and high SPAG5-protein were associated with shorter BCSS 
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[Uppsala: (HR (CI 95%): 1·62 (1·03-2·53) p=0·036); METABRIC: (HR (CI 95%): 1·27 
(1·02-1·58) p=0·034); Desmedt-untreated LN- cohort: (HR (CI 95%): 2·34 (1·24-
4·42) p=0·0090), and Nottingham-HES-BC (HR (CI 95%): 1·73 (1·23-2·46) 
p=0·0020); respectively].  
In ER-negative-BC with high SPAG5-protein, administration of anthracycline-
adjuvant-chemotherapy had reduced the risk of death by 60% compared to 
chemotherapy-naive (HR (95% CI): 0·37 (0·20-0·60); p=0·0010).  A multivariable 
Cox regression analysis, which included other validated prognostic factors for 
chemotherapy (e.g., menopausal status, size, lymph node stage,  histologic grade, 
ER, PR, HER2, Bcl2, chemotherapy, interaction term of SPAG5 and both 
chemotherapy[y), revealed that SPAG5-transcript+ was independently associated 
with decreased risk of DRFS after receiving Taxane/anthracycline-Neo-ACT 
[MDACC-T/AC-Neo-ACT: (HR (CI 95%): 0·68 (0·48-0·97); p=0·0070)]. 
In multivariable logistic regression analysis, both SPAG5-transcript+ and SPAG5-
protein+ and were independent predictors for higher pCR after combination-cytotoxic 
chemotherapy [MDACC-T/AC-Neo-ACT: (OR (95% CI) 1·71 (1·07-2·74); p=0·024), 
and Nottingham-AC-Neo-AC: (OR (95% CI): 8·75 (2·42-31); p=0·0010); 
respectively].  
Interpretation:    
SPAG5 is a novel amplified gene on Ch17q11.2 in PAM50-LumB and PAM-HER2 
BC, and its transcript and protein products are independent prognostic and predictive 
biomarkers, with potential clinical utility as a biomarker for combination cytotoxic 
chemotherapy sensitivity, especially in ER- BC.   
Funding: 
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Nottingham Hospitals Charity and the John and Lucille van Geest Foundation.   
10 
 
Words=3000 
Introduction 
Approximately 1·68 million women are diagnosed with BC worldwide annually, with 
over 500,000 dying of the disease (~1,400 per day).1  Despite continuing success, 
the delivery of effective precision medicine requires: 1) the discovery of novel 
therapeutic targets in subgroups of BC, and 2) improvements in the efficacy  of 
treatments by identifying stratification biomarkers that can predict an individual 
patient’s response to a particular therapy.2 Although chemotherapy is offered to 
approximately 60% of patients with BC,3 either alone or in combination with other 
targeted-therapies, a meta-analysis of 123 randomized trials involving over 100,000 
patients has concluded that chemotherapy reduces recurrence and mortality rates by 
only 20-33%.4  Although a St Gallen International Expert Consensus recently 
recommended the use of proliferation markers/profiles when choosing the 
appropriate systemic-treatment, the best molecular-marker/test that should be used 
continues to be debated.5 
The main aim of the current study was to identify a biomarker that could drive 
proliferation and could be used to stratify BC patients’ outcome. To achieve this, we 
decided to apply an artificial neural network (ANN) algorithm 6 to three gene 
expression datasets, and use factors that are directly and indirectly related to 
proliferation, defined as clinical class questions, to train it. The most prominent 
genes in the resulting interactome-map would then be developed and the best 
followed up, through an integrated analysis at the levels of copy number aberrations 
(CNAs), mRNA transcript and protein, in order to assess the clinico-pathological 
implications and utilities in a combined total of over 10,000 patients. Here we present 
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the results of our ANN analysis, and the gene SPAG5 (Sperm-associated antigen 5), 
which featured prominently in the interactome -map of proliferation and had a great 
impact on patients’ survival.   Given that SPAG5 has a fundamental role in the 
function and dynamic regulation of mitotic spindles, and in mitotic progression and 
chromosome segregation fidelity, 7 we hypothesized that SPAG5 could be a better 
measurement of proliferation activity and provide a more accurate guide for the 
delivery of systemic therapies in BC.  
Patients and Methods  
Study design and cohorts 
Study design, patient’s cohorts and demographics used in this study are summarized 
in Fig.1 and appendix p1-3. 
All patients completed written informed consented, as per hospital standard of care, 
for excess tumour tissue to be used in research. The study was approved by the 
Institutional Review Board or Independent Ethics Committee and the Hospital 
Research and Innovations Department at all participating sites. Tumour Marker 
Prognostic Studies (REMARK) criteria, as recommended by McShane et al, 8 were 
followed throughout this study.  
I) Identification of proliferation drivers and validation the prognostic function 
of SPAG5-CNAs, transcript and protein expression in BC 
A) Discovery cohort: Nottingham discovery (ND) cohort (n=171) 
The ANN modelling-based data mining approach to identify factors that drive 
proliferation and its associated features in BC was explored in the ND cohort, 
consisting of a set of 171 stage I and II invasive BC with a median follow-up of 180 
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months (IQR 143-194), previously described by our group in several molecular 
profiling studies.9 This cohort has also been used for exploring the integrated 
analysis of SPAG5 CNAs, transcript, and protein expression.  
B) Test cohort: Uppsala (n=249)  
The ANN modelling-based data mining approach and the clinicopathological 
significance of SPAG5 gene expression were tested in the Uppsala cohort 
composed of 315 women representing 65% of all BCs resected in Uppsala County, 
Sweden (1987-1989) with a median follow-up of 126 months (IQR 119-134).10 Gene 
expression data were available for only 249 patients. 
C) Validation cohorts: 
1) METABRIC (Molecular Taxonomy of Breast Cancer International 
Consortium) cohort (n=1980)  
The ANN modelling-based data mining approach and integrated SPAG5-CNA and 
SPAG5-trancript analysis was validated using the METABRIC cohort; a set of 1980 
BCs with median follow-up of 109 months (IQR 62-155).11   In this cohort, oestrogen 
receptor (ER) positive and/or lymph-node (LN) negative patients did not receive 
adjuvant chemotherapy (ACT), whereas ER-negative and/or LN-positive patients 
received ACT. Additionally, none of the human epidermal growth factor receptor-2 
(HER2)-overexpression patients received trastuzumab. 
2) Untreated lymph-node negative BC cohorts:  
The prognostic significance of SPAG5-mRNA expression was assessed in three 
publically available datasets of LN-negative BC (n=684). These patients did not 
receive any adjuvant systemic therapy, thereby allowing the effect of SPAG5-
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transcript on the natural history of the disease to be observed. These datasets were 
described in previous publications by Wang et al 12 (n=286), Desmedt et al 13 
(n=196), and Schmidt et al 14 (n=200).  The median follow up of each cohort is 
summarized in appendix p1-3.  
3) Multi-Centre Combined cohorts (MCC; n=5439) 
We evaluated the prognostic utility of SPAG5-mRNA expression in a large combined 
BC cohort which was sourced from 36 publically-available, global datasets (n=5439) 
using the online bc-GenExMiner program (http://bcgenex.centregauducheau.fr). 15   
A list of all the datasets, with references, is summarized in appendix p4-6. 
4) Nottingham Historical early stage BC cohort (Nottingham-HES-BC; n=1650)  
The clinicopathological significance and prognosis of SPAG5 protein expression was 
also validated in a cohort of BC (n=1650; age>71 years) 16 whose tissues were 
suitable for SPAG5 immunohistochemistry (IHC). These patients were diagnosed 
and treated uniformly between 1986 and 1999 at the Nottingham City Hospital 
(NCH), Nottingham, UK. Patients within the good prognosis group (Nottingham 
Prognostic Index (NPI) <3·4) did not receive systemic adjuvant therapy. Pre-
menopausal patients within the moderate and poor prognosis groups were 
candidates for CMF chemotherapy (cyclophosphamide 750 mg m−2, methotrexate 50 
mg m−2 and 5-fluorouracil 1 g m−2, on day 1 of a 21-day cycle.). Conversely, 
postmenopausal ER-positive patients with moderate or poor NPI were offered 
hormonal therapy, whereas ER-negative patients received CMF chemotherapy. 
Clinical data were maintained on a prospective basis with a median follow-up of 143 
months   (IQR 114-174). 16.  The median follow up of subgroups is summarized in 
appendix p1-3. 
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II) The clinical significance of SPAG5-protein and SPAG5-transcript expression 
in the context of currently used chemotherapy in BC  
In order to evaluate the value of SPAG5 transcript and protein expression as a 
biomarker in the context of current combination cytotoxic chemotherapy, we further 
evaluated the clinical significance of SPAG5 protein and transcript expression in 
adjuvant and neo-adjuvant chemotherapy settings.  
1. Nottingham early stage ER-negative BC adjuvant chemotherapy cohort 
(Nottingham-ER-negative ; n=697) 
To evaluate the survival benefit of SPAG5-protein expression, we analysed its 
expression in a consecutive series of 697 early stage ER-negative BC’s who had 
been diagnosed and managed at NCH between 1999 and 2007.  This series 
included: 1) The ER-negative BC patients of Nottingham historical early stage BC 
cohort (n=332) who were managed before 2000 and treated either with no 
chemotherapy or with adjuvant CMF; and 2) the new ER-negative early stage BC 
patients (n=365) who were managed after 2000 and received either no 
chemotherapy or anthracycline-based-ACT (AC-ACT). 17 The median follow up of 
different treatment subgroups is summarized in appendix p1-3. 
2. Nottingham anthracycline based Neo-Adjuvant Chemotherapy cohort 
(Nottingham AC-Neo-ACT; n=200) 
The relationship between SPAG5-protein expression and response to chemotherapy 
was evaluated by investigating its expression in pair-matched pre-chemotherapy 
core biopsies and post-chemotherapy surgical specimens, from 200 female patients 
with locally-advanced primary BC (LAP-BC) (stage IIIA-C) that had been treated with 
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anthracycline-based Neo-ACT (AC-Neo-ACT) 18 at NCH between 1996 and 2012.  
Sixty three percent of patients (127/200) received six cycles of an anthracycline-
based therapy (FEC: 5-fluorouracil (5-FU) 500 mg m−2, epirubicin 75–100 mg m−2, 
cyclophosphamide 500 mg m−2, on day 1 of a 21 day cycle), whereas 37% of 
patients received FEC plus Taxane (73/200). All patients underwent mastectomy or 
breast-conserving surgery and axillary dissection, followed by adjuvant radiation 
therapy. Patients with ER-positive BCs were offered 5 years of adjuvant endocrine 
therapy.  The median follow-up time was 67 months (IRQ 27-81). 
University of Texas MD Anderson Cancer Centre-Taxane/Anthracycline-based 
neo-adjuvant chemotherapy cohort (MDACC-T/AC-Neo-ACT; n=508) 
The relationship between SPAG5-transcript expression and response to 
chemotherapy was evaluated using MDACC-T/AC-Neo-ACT cohort in which patients 
were selected for newly diagnosed HER2- negative BC and treated with sequential 
taxane and anthracycline–based neo-adjuvant chemotherapy (then endocrine 
adjuvant therapy if ER-positive). Details of patients’ characteristics have been 
previously reported. 19 The median follow-up time was 38 months (IRQ 26-53). 
3. Multicentre phase II AC-Neo-ACT clinical trial cohort (NCT00455533; 
n=253) 
The relationship between SPAG5-transcript and the response to AC-Neo-ACT was 
validated using a randomised, open-label, multicentre, phase II clinical trial 
(NCT00455533) in which women with early stage BC (T2–3, N0–3, M0, tumour size 
2·0 cm) have received AC-Neo-ACT regimens (cyclophosphamide plus doxorubicin 
(AC), followed by ixabepilone or paclitaxel).  Full details of the study design and the 
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patient characteristics have been described previously. 20 Out of 295 patients 
enrolled into the trial, 253 patients had available gene expression and pCR data.  
Procedures 
1- The ANN modelling-based data mining approach  
To identify factors that could drive proliferation and its associated features in BC, a 
number of factors that are directly and indirectly related to proliferation, defined as 
clinical class questions (e.g. histological-grade; mitotic index (MI); MKi67; TOP2A; 
KIF2C; BIRC5 and 5-year-survival), were analysed by applying an ANN modelling-
based data mining approach in three gene expression array transcriptomic datasets, 
that included the ND, Uppsala and METABRIC cohorts.  The ANNs have been 
selected to data mine the clinical data sets identified in this study as they have 
previously been shown to be able to identify biomarkers, with high sensitivity and 
specificity that predict clinical features with excellent validity for unseen data sets. 6 
In additions, ANNs unlike conventional statistical approaches (such as hierarchical 
clustering, principal components analysis or linear regression) are not limited by 
linear functionality; this provides improved representation of biological features. The 
ranked orders of genes, produced in this way were compared across multiple 
proliferation related clinical class questions within a given dataset. The top 100 
ranked genes for predicting each clinical class question, based on minimum average 
route mean squared error, were compared and commonalities identified at the probe 
level. Further comparisons were then made for the same clinical class questions in 
the other datasets in order to determine a consensus list of gene probes across all of 
the features and data sets.  The strongest 100 integrated interactions were selected 
for visualisation in Cytoscape (Version 3.1.1, The Cytoscape Consortium; San-
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Francisco, USA). 21   Further details of the ANN approach is presented in appendix 
p7-10.  
2- SPAG5 CNAs 
CNAs at the SPAG5 locus on chromosome 17q11.2 were retrieved from both high 
resolution (<100 kb) oligonucleotide microarrays, comparative genomic hybridization 
(aCGH; ND cohort), and Affymetrix SNP 6.0 platform profiling (METBRIC cohort), 
that has been previously described by our group. 9, 11 The oligonucleotide array data 
can be access at (http://www.ncbi.nlm.nih.gov/geo/; series accession number-
GSE8757) whereas SNP data are available through the European Genotype Archive 
(http://www.ebi.ac.uk/ega/page.php) under accession Number: EGAS00000000082). 
An additional analysis considered a set of 85 individuals of European ancestry for 
whom genotyping was performed on non-cancerous tissue and gene expression 
values from matched normal tissue were available.11 
3- SPAG5 and MKi67 gene expression 
SPAG5 and MKi67 mRNA expression data were retrieved and analysed in the 
following cohorts:- ND [using Agilent gene expression arrays at 
(http://www.ebi.ac.uk/miamexpress/ with accession number E-TABM-576), Uppsala 
[using Affymetrix U133A&B Gene-Chips microarray profiling data at 
(http://www.ncbi.nlm.nih.gov/geo/) with series accession number (GSE4922)], and 
METABRIC [using Illumina HT-12 v3 platform (Bead Arrays)11 data at 
(http://www.ebi.ac.uk/ega/page.php) under accession Number 
(EGAS00000000082)].    In addition, the SPAG5 and MKi67 mRNA expression data 
has been retrieved for three publically available datasets of LN-negative BC  in which 
patients did not receive any adjuvant systemic therapy: Wang et al12 (accession 
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number: GSE2034; n=286), Desmedt et al13 (accession number: GSE7390; n=196), 
and Schmidt et al14 (accession number: GSE11121; n=200).  For the MCC cohort, 
details of the gene expression data processing, normalization and the statistical tests 
have been described previously. 15 In this cohort, gene expression data  were 
converted to a common scale (median equal to 0 and standard deviation equal to 1) 
in order to merge all of the studies data and create combined cohorts (for more 
details see appendix p8). 22 The gene expression data for the MDACC-T/AC-Neo-
ACT cohort and the phase II clinical trial (NCT00455533) has been downloaded 
using accession number GSE25066 and GSE41998; respectively. 
4- Immunohistochemistry (IHC) staining of SPAG5 and Ki67  
The ND, Nottingham-HES-BC, Nottingham-ER- and Nottingham-AC-Neo-ACT 
cohorts were IHC profiled for SPAG5, Ki67 and other biological parameters.  Tissue 
microarrays (TMAs), as described in detail in appendix p8-12 have been used for 
IHC profiling of SPAG5 in all cohorts except in Nottingham-AC-Neo-ACT where full-
face sections of core biopsies have been used.    
Determination of the cut-offs 
The median in each cohort was used as cut-off between low and high expression 
gene/protein expression 
Outcomes: 
The clinicopathological and biomarkers associations: The clinicopathological 
and molecular characteristics of SPAG5 transcript were determined in the Uppsala, 
METABRIC, MCC and MDACC-T/AC-Neo-ACT cohorts.  SPAG5–CNA moleculo-
pathological associations were analysed in METABRIC cohort.   The associations 
between SPAG5 protein expression and clinicopathological parameters, as well as 
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prognostic biomarkers, were analysed in the Nottingham-HES-BC, the Nottingham-
ER-negative and the Nottingham-AC-Neo-ACT cohorts. The clinicopathological 
parameters including mainly: tumour size, LN- stage, histological grade, genomic 
grade index (GGI), TP53 mutation, intrinsic molecular subclasses, PAM50, HER2 
amplification/overexpression, hormone receptors, Ki67, mitotic index, Bcl2 and other 
biological biomarkers.   
Breast cancer specific survival (BCSS): SPAG5 transcript expression association 
with BCSS was explored in the ND cohort and validated in Uppsala, METABRIC and 
the untreated LN-negative Desmedt et al cohorts.  SPAG5-CNAs association with 
BCSS was tested in METABRIC cohort whereas the association between SPAG5 
protein expression and BCSS was analysed in the ND cohort, Nottingham-HES-BC 
cohort and Nottingham-ER-negative cohorts.   
Disease free survival (DFS): SPAG5 transcript expression association with DFS 
was examined in untreated LN-negative cohorts (Wang et al and Desmedt et al), 
MCC and Nottingham-AC-Neo-ACT cohorts.   
Distant relapse free survival (DRFS):  SPAG5 transcript expression association 
with DRFS were determined in untreated LN-negative Schmidt et al and Desmedt et 
al cohorts.  Furthermore, to test SPAG5 transcript expression as a biomarker for 
outcome after neo-adjuvant combination cytotoxic chemotherapy, their association 
with DRFS has been analysed in the MDACC-T/AC-Neo-ACT cohort.  
Pathological complete response (pCR) and residual cancer burden (RCB): To 
evaluate SPAG5 protein and transcript expression as a predictive biomarker for 
response to combination cytotoxic chemotherapy, their associations with both pCR 
and RCB 23 have been analysed in the Nottingham-AC-Neo-ACT,  the MDACC-
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T/AC-Neo-ACT, and the phase II AC-Neo-ACT clinical trial cohort (NCT00455533); 
respectively. The pCR was defined as the absence of any residual invasive 
carcinoma at both the primary site and in axillary LNs. 
Statistical analysis were performed using STATISTICA (Stat Soft Ltd, Tulsa, USA) 
and SPSS (version 17, Chicago, USA) by the authors (TAF, GRB) who were blinded 
to the clinical data. The Chi-square test was used for testing associations between 
categorical variables, and a multivariable Cox model was fitted to the data using 
survival time as the endpoint.  All tests were two-sided with a 95% CI and a p value 
of <0·050 was considered to be indicative of statistical significance. Multiple-testing 
correction was applied to all p-values using the Bonferroni method. The range of 
corrections were (5 - 48,803) across the different analyses.  Gene-dosage levels to 
gene expression were evaluated using the Jonckheere's trend test in order to 
evaluate the significance of the correlation between CNAs and aberrant gene-
expression. Pearson correlations between mRNA expression log intensity values 
and SPAG5 protein expression (H-score) were used to determine whether mRNA 
expression levels correlated with protein levels. See appendix p8-9 for details. 
Power analysis and false discovery correction 
Power analysis for the ANN model was conducted using a logistic regression power 
model (of which ANNs are an extension with a greater power), using G*Power 3.1.9 
software (Heinrich Heine University of Dusseldorf, Dusseldorf, Germany). 24 To 
determine sample size, an alpha of 0·050, a power of 0·80, an effect size (odd ratio 
= 1·72) and two-tailed test, were chosen for binary questions or classes (e.g., low 
vs., high expression).  Based on the assumptions of the power model, the desired 
sample size is 88 (44 in each low and high class). The use of a Monti Carlo cross 
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validation (MCCV) strategy was further used to prevent false discovery, over-fitting 
and to increase the power of the algorithm used (see appendix p7 for detail). By 
repeatedly testing on an unseen data set and stopping accordingly, over-fitting is 
prevented. False discovery is further reduced in this study by parallel analysis on 
multiple questions in multiple datasets.  With each separate analysis reducing the 
probability that a gene could be discovered by random chance, and yet still be a 
common result across multiple analyses, of separate datasets.  
The probability (p) of the 30 genes occurring as common in the top 100 out of the 
whole expression array for the three cohorts for a minimum of 4 proliferation-related 
factors = 1·43x10-31 (see the calculation in appendix p7).   
A retrospective power analysis was conducted to determine the confidence in the 
calculated hazard ratio and associated p value for 10 year survival and to ascertain 
how applicable the result would be to a global population.  The power of study was 
determined using PASS software (NCSS, version 13, Utah, USA).  
Results 
Our ANN analysis in three cohorts (ND, Uppsala and METABRIC cohorts) identified 
the top 100 ranked genes that predict most of the proliferation-related features 
(appendix p13-27). We chose to further study the clinicopathological implication of 
SPAG5 because it was found to be among 30 common gene-probes that were 
predictive across most of the proliferation features and datasets, and it features 
prominently in the interactome maps (appendix p25-27).  In addition, in a small set of 
BC, investigators found that SPAG5 transcript was a mong few genes that were 
associated with poor prognosis in ER-positive BC.25   Because Ki67 has been used 
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by many investigators as a marker for proliferation when choosing the appropriate 
systemic-treatment, subsequently we chose to be used it as a control in our study.   
Gain/amplification at the SPAG5 locus (17q11·2) occurred in 16% (26/171) and 
10·4% (206/1980) of BC, in the ND and METABRIC cohorts respectively. SPAG5-
gain/amplification was more common in high-grade, PAM50-HER2, and PAM50-
LumB.  A strong correlation between SPAG5-CNA and SPAG5-transcript expression 
was apparent (ND cohort: Spearman-correlation r=0·81; Bonferroni-adjusted-
p=0·010) and METABRIC: Spearman-correlation r=0·87; Bonferroni-adjusted-
p<0·0001). ER-negative and ER-positive BC exhibited a higher level of SPAG5-
transcript (correlation-coefficient=0·19; Bonferroni-adjusted-p<0·0001 and 
correlation-coefficient=0·37; Bonferroni-adjusted-p<0·0001; respectively) compared 
to normal individuals (n=85). However, the level of SPAG5-transcripts in ER-negative 
disease was higher than that in ER-positive disease (correlation-coefficient=0·18; 
Bonferroni-adjusted-p<0·0001). Furthermore, the PAM50-LumB, PAM50-Basal and 
PAM50-HER2+ BC-subclasses exhibited higher levels of SPAG5-transcripts than 
PAM-50-normal-like, PAM50-Lum-A disease, and normal tissue (all-adjusted-
p<0·0001; Figure appendix p28).   
As a continuous and categorical variable, compared to low SPAG5-transcript 
expression, high SPAG5-transcript level (>median) was associated with high-grade 
TP53- mutation, and HER2 gain/amplification. In the METABRIC study, 10-novel-
prognostic biological subgroups have been identified by the joint clustering of CNA 
and gene expression data (integrative-clusters (intClust)). 11 Herein, SPAG5-
gain/amplification was shown to be associated with intClust-1, 5, and 6 (all-
p<0·0001) whereas high SPAG5- was associated with intClust-1, 5, 9, and 10; 
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appendix p29-32. Furthermore, high SPAG5-transcript expression (>median) was 
associated with other molecular parameter/indices/subclasses that predict higher 
probability of response to Neo-ACT: RCB-0/I,23 genomic-chemo-sensitivity predictor, 
19  genomic-excellent-pathologic-response predictor, 19 96-gene-genomic-grade 
index (GGI), 26 diagonal linear discrimination analysis of 30-gene  signature 
(DLDA30), 27 and PAM-50-gene signature 28 (all p<0·0001, appendix p33). 
Additionally, there was a strong correlation between SPAG5-transcript and SPAG5-
protein expression (Pearson-correlation (r=0·75); Bonferroni-adjusted-p=0·001).  In 
the Nottingham-HES-BC cohort, 20% (272/1368) of patients showed high SPAG5-
protein (H-score≥10) that was associated with aggressive phenotypes including 
HER2+ (p=0·030), Luminal-B (ER+/HER-/high-Ki67), an absence of hormone 
receptors, and TP53-mutation (appendix p34-37). In the Nottingham-ER-negative 
cohort, high SPAG5-protein (H-score>10) was observed in 51% (355/697) and was 
associated with lympho-vascular-invasion, high-grade, and high-ki67 (all p<0·0001; 
appendix p38-41). In Nottingham AC-Neo-ACT locally advanced BC cohort, high 
SPAG5-protein (H-score>10) was observed in 25·0% (50/200) of pre-chemotherapy 
core biopsies and was associated with high-grade, Luminal-B (ER+/HER2-/high 
Ki67), ER-/HER-negative, and TP53-mutation (all adjusted p<0·0001). Among 
different cohorts neither SPAG5 transcript nor protein was associated with LN stage 
or disease clinical stage.  
SPAG5-gain/amplification was associated with shorter BCSS than SPAG5-
normal/loss in all patients (HR (CI 95%):1·50 (1·18-1·92); p=0·0016) and the ER-
positive subgroup (HR (CI 95%): 1·55 (1·18-2·04); p=0·00020), but not in ER-
negative  tumours (HR (CI 95%): 1·58 (0·97-2·56), p=0·065) (Fig.2A-C); METABRIC 
cohort.   
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As continuous variables, high SPAG5-transcript expression levels was associated 
with shorter BCSS than low SPAG5-transcript [ND cohort: (HR (CI 95%):1·50 (0·98-
2·32); p=0·065), Uppsala cohort: (HR (CI 95%): 1·99 (1·44-2·76); p<0·0001) and 
METBRIC cohort: (HR (CI 95%): 1·89 (1·55-2·31); p<0·0001)].  As a categorical 
variable high SPAG5-transcript (>median), was associated with shorter BCSS than 
low SPAG5-transcript [Uppsala: (HR (CI 95%): 1·98 (1·29-3·04); p=0·0020), and 
METABRIC: (HR (CI 95%): 1·68 (1·40-2·01); p<0·0001, Fig2D).  High SPAG5-
transcript was associated with shorter BCSS than low SPAG5-transcript in ER-
positive sub-groups but not in ER-negative tumours (Fig.2E-F). Also, in the low-risk 
BC (NPI≤3·4), LN-negative, as well as LN-positive (METABRIC), high SPAG5 
transcript was associated with shorter BCSS than low SPAG5 transcript (Figure 
appendix 42). In Uppsala cohort with 249 cases (124 in the high SPAG5 transcript 
group) achieved a power of 83% to detect a hazard ratio (HR) of 1·98 , when the 10 
years survival rate for high and low SPAG5 transcript are 53% and 71%; respectively 
and p value <0·050.  Similarly for the METABRIC cohort transcript expression 
analysis, a power model using a two-sided log-rank test with an overall sample size 
of 1950 subjects (970 in the high SPAG5-transcript groups) achieved a power in 
excess of ≥99·9% to detect a hazard ratio (HR) of 1·68, when the proportion 
surviving (BCSS) to 10 years in the high SPAG5 and low SPAG5 are 78% and 66%; 
respectively, with p <0·0001.   
In untreated LN-negative cohorts high SPAG5 transcript (>median) was associated 
with shorter DSF, DRFS and BCSS than low SPAG5 transcript (Fig.2G-I]. In the 
untreated LN-negative-BC cohorts: Wang et al (n=286; 143 cases with high SPAG5), 
Schmitt et al (n=200; 100 cases with high SPAG5), and Desmedt et al (n=198; 99 
cases with high SPAG5), the retrospective power of each to detect HRs of 1·3, 1·4, 
25 
 
and 1·99, at ten years of DFS, DRFS and BCSS was 82%, 84%, and 98%; 
respectively, with p<0·050.   
In the Uppsala cohort multivariable Cox regression analysis including patient age, 
LN-stage, tumour-size, GGI, ER status, TP53 mutation and MKi67-transcript, 
revealed that high SPAG5-transcript and LN-stages were independently associated 
with increased-risk of death (Table-1A).  Similarly in the METABRIC cohort, a 
multivariable Cox regression model which included patient age, tumour size, grade, 
LN-stage, HER2, ER, PR, hormone-therapy, and chemotherapy, demonstrated that 
high SPAG5-transcript was independently associated with shorter BCSS (Table-1B).  
Furthermore, multivariable Cox regression models showed that high SPAG5-
transcript was associated with clinical outcome independently of both PAM50 and 
intClust prognostic subclasses (Table 1C-D).  In addition, in the untreated LN-
negative Desmedt et al cohort, high SPAG5-transcript was associated with shorter 
BCSS after adjustment for ER status and other prognostic signatures/indices such 
as 76-gene prognostic signature (Veridex)13, Adjuvant-Online (AOL) and the NPI 
(Table 1-E). 
In the MCC cohort high SPAG5-transcript (>median) was associated with increased 
risk of relapse compared to low SPAG5-transcript expression in all patients and LN-
negative, LN-positive, and ER-positive BC subgroups, but not in the ER-negative-
subgroup (Figure appendix p43).  In MCC, with an overall sample size of 5439 (2711 
in high SPAG5), a ≥99·9% power to detect a HR of 1·68 for DFS, with p-value 
<0·0010, was achieved.  In the MCC cohort, multivariable Cox regression models 
confirmed that the high SPAG5-ranscript is an independent poor prognostic factor 
after controlling for NPI (HR (CI 95%): 1·19 (1·09-1·30); p=0·00020), AOL (HR (CI 
95%): 1·18 (1·03-1·35); p=0·017), and 72-proliferation-gene-signature 29 (HR (CI 
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95%): 1·18 (1·10-1·27); p<0·0001). Univariate analysis showed that high MKi67 
transcript expression was associated with a higher risk of relapse compared to low 
MKi67 expression. However, multivariable Cox regression models revealed that 
MKi67 transcript expression was not an independent prognostic factor for BC after 
controlling for NPI (HR (CI 95%): 1·09 (1·00-1·20); p=0·060) and AOL (HR (CI 95%): 
0·93 (0·83-1·05); p=0·26). 
Similarly high SPAG5-protein expression was associated with shorter BCSS than 
low SPAG5-protien expression (ND: HR (CI 95%): 1·06 (1·02-1·09), p=0·0010, and 
Nottingham-HES-BC cohorts: HR (CI 95%): 1·68 (1·32-2·12), p<0·0001; Fig.3A]. 
SPAG5-protein+ was also associated with increased-risk of death in ER-positive 
subgroups (Fig.3B), but not in ER-negative subgroups (Fig.3C). In the low-risk 
(NPI<3·4), LN-negative, as well as LN-positive subgroups high SPAG5 protein 
expression was associated with shorter BCSS than low SPAG5 (Figure appendix 
p44). For the ND and Nottingham HES BC cohort, with an overall sample size of 128 
and 1342 subjects (24 and 273 cases in the high SPAG5-protein subgroups), 80% 
and 99·0% powers to detect a HR of 1.10 and 1·68 is achieved with p-value <0·050, 
when the proportion surviving in the SPAG5+ subgroup at ten year of BCSS is 60% 
and 63%; respectively.   
Multivariable Cox regression analysis reveals that high SPAG5-protein was 
independently associated with a poorer BCSS at 10 years compared to low SPAG5 
expression, after adjustment for adjuvant hormone-therapy and chemotherapy, 
grade, size, LN-stage, HE2, ER, PR, age, Ki67 and interaction-terms (SPAG5* 
chemotherapy and SPAG5* hormone-therapy); Table 1F.  
27 
 
In the Nottingham-ER-negative cohort, high SPAG5-protein was associated with 
decreased risk of death from BC (HR (95% CI): 0·85 (0·78-0·94); p=0·0010) (Fig.3D) 
compared to low SPAG5-protein expression. However, a subgroup analysis of ACT-
naïve cases showed that patients with high and low SPAG5-protein expression 
exhibited similar BCSS (HR (95% CI): 0·90 (0·63-1·27); p=0·54), whereas in the 
subgroup that received ACT; high SPAG5-protein exhibited lower risk of death that 
low SPAG5-protein level (HR(95% CI): 0·41 (0·26-0·64); p<0·0001) (Figure appendix 
p45). In ER-negative BC with high SPAG5-protein, administration of anthracycline-
ACT had reduced the risk of death by 60% compared to chemotherapy-naive (HR 
(95% CI): 0·37 (0·20-0·60); p=0·0010) (Fig.3E). Meanwhile administration of 
anthracycline-ACT had no impact on tumours with ER-negative /low SPAG5-protein 
phenotype (Fig.3F). A multivariable Cox regression model confirms that SPAG5 was 
a predictive marker and that the interaction-term between SPAG5-protein and the 
administration of anthracycline-based adjuvant chemotherapy was a significant 
predictor of BCSS (Table-1G). 
In the MDACC-T/AC-Neo-ACT cohort, after receiving combination cytotoxic 
chemotherapy,   there was a marginally shorter DRFS in those patients with high 
SPAG5-transcript tumours compared to those with low SPAG5 (HR (CI 95%): 1·3 
(0·92-1·95); p=0·12; appendix p43). In those patients that did not achieve pCR, high 
SPAG5-transcript was significantly associated with shorter DRFS than those with low 
SPAG5-transcript (HR (CI 95%): 1·74 (1·17-2·52); p=0·0070; appendix p46). A 
multivariable Cox regression analysis which included other prognostic factors for 
chemotherapy, namely genomic-chemo-sensitivity predictor, GGI, DLDA30, PAM-50-
genes, American joint committee of cancer (AJCC) stages, and MKi67 transcript, 
revealed that high SPAG5 was independently associated with decreased risk of 
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distant relapse after receiving Neo-ACT (HR (CI 95%): 0·68 (0·48-0·97); p=0·0070; 
Table1H). 
To validate our previous observation, we investigated the relationship of SPAG5 
transcript expression and response to combination cytotoxic chemotherapy in the 
MDACC-T/AC-Neo-ACT cohort (n=508) in which 488 cases had pCR data were 
available.  Of them, 20% (99/488) achieved pCR.  As a continuous variable, high 
SPAG5-transcript levels were associated with higher pCR compared to low SPAG5-
transcript (OR (CI 95%): 2·6 (1·8-3·9); p<0·0001).  As a categorical variable, high 
SPAG5-transcript (>median) was association with higher pCR; 29% (70/246) vs 12% 
(29/242) for low SPAG5-transcript (OR (95% CI): 2·90 (1·80-4·70), p<0·0001). 
Multivariable logistic regression analysis including parameter/indices/subclasses that 
associated with higher pCR as well as: AJCC clinical stage, histological grade, ER, 
PR, and patient age, demonstrated that high SPAG5-transcript was an independent 
predictor for higher pCR (Table-2A).   
We further validated our results in a multicentre phase II anthracycline-based-Neo-
ACT clinical trial cohort (NCT00455533) 20 in which 27% (69/253) and 34% (86/253) 
of patients achieved pCR and RCB-0/RCB-1 rates, respectively.  As a continuous 
variable, SPAG5-transcript expression was associated with a marginally higher 
incidence of pCR and RCB-0/RCB-1 ((OR (CI 95%): 1·33 (0·98-1·79); p=0·065) and 
(OR (CI 95%): 1·29 (0·98-1·71); p=0·075); respectively).  Using the median to 
categorize SPAG5-transcript expression into (high) and (low); high SPAG5-transcript 
was associated with higher pCR and RCB-0/RCB-1 rates ((OR (CI 95%): 1·99 (1·13-
3·45); p=0·016) and (OR (CI 95%): 1.97 (1·16-3·34); p=0·010), respectively) 
compared to low SPAG5-transcript. In a multivariable logistic regression model 
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which included ER, PR, HER2, tumour size, menopausal status, and MKi67, and 
SPAG5 transcript expression, SPAG5-transcript was significantly associated with 
RCB-0/RCB-1 (Table 2B). 
Similar to transcriptomic findings, patients with high SPAG5-protein (H-score>10) 
disease prior to chemotherapy, who received AC-Neo-ACT, exhibited similar 5-year 
DFS following surgery (HR (95% CI): 1·1 (0·90-1·30); p=0·40) to those with low 
SPAG5-protein- disease (appendix p43). Importantly, patients with high SPAG5-
protein expression in the residual tumour specimen after receiving AC-Neo-ACT 
were at a higher risk of relapse (HR (95% CI): 2·2 (1·2-4·2); p=0·010) compared to 
those with low SPAG5-protein residual tumours, at the 5-year follow-up (Figure 
appendix p46). In the Nottingham-AC-Neo-ACT cohort, 14·5% (29/200) of patients 
had achieved pCR and 40% (20/50) of patients with high SPAG5-protein BC 
achieved pCR compared to 6% (9/150) of those with low SPAG5-protein disease 
(OR (CI 95%): 10·8 (4·5-26·29); p<0·0001; appendix p43). Furthermore, 37% 
(18/49) of BC that exhibited high SPAG5-protein disease became negative for 
SPAG5-protein after receiving AC-Neo-ACT (McNemar-test; p=0·0040).  
Multivariable logistic regression analysis revealed that high SPAG5-protein was an 
independent predictor of pCR, whereas Ki67 was not, after controlling for age, 
taxane, grade, AJCC stage, ER, HER2, Ki67, Bcl2, and TOP2A (Table-2C).   
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Discussion 
To our knowledge this is the first multi-dimensional study to report on the clinico-
pathological utilities of SPAG5 in BC in more than 10,000 patients. Our findings 
suggest that: 1) Amplification/gain of the SPAG5 locus at Ch17q11·2 occurred in 10-
20% of BC, 2) The SPAG5-gene-CNA and its transcript and protein were associated 
with poor clinical outcome and adverse clinicopathological features, including TP53-
mutation, PAM50-LumB, and PAM50-Her2, 3) Both SPAG5 transcript+ and protein+ 
are independent predictors for response to chemotherapy.  
Recent advances in molecular biology have generated a huge amount of data, which 
has then been used to generate multigene-profiles for guiding chemotherapy 
treatment. Unfortunately, almost all of these approaches face common issues such 
as insufficiently high levels of evidence, the over-fitting of computational models, 
false discovery rates, 30 and the lack of a potential biological mechanism to support 
their use as predictors of therapeutic response. Furthermore, they do not offer a 
significant improvement in predictive accuracy over the well-established pathological 
parameters or the cheaper, conventional immunohistochemistry approach, and may 
not be available for logistical or financial reasons. 31 In fact, the majority of the 
prognostic power of these assays comes from genes that are related to cell 
proliferation. The data presented herein are significant as the prognostic and 
predictive capacities of SPAG5 have been shown to be independent of many of 
these multigene tests and Ki67. Furthermore, our integrated network inference 
bioinformatics analysis has revealed that MKi67 was less influential on other 
proliferation factors, and lacked the centrality of other probes.   
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In agreement with the results of data mining the Oncomine-microarray database, we 
found BC, like most human cancers, exhibited a higher level of SPAG5-transcript 
expression compared to normal tissue (appendix 47-53), which in turn is associated 
with poor clinical outcome (appendix 54-56), especially in ER+ BC. 25 In agreement 
with a previous study, we have reported a high level of Ch17q11·2 amplifications in 
HER2+ and ER+ BC, 32 which is the locus of SPAG5. Recently, duplication of CEP17 
has been proposed as a marker of chromosomal instability, spindle assembly 
checkpoint deregulation, and it has been linked to anthracycline-sensitivity in vitro 
and to clinical outcome of AC-ACT. 33 Likewise, given that SPAG5 has an essential 
role in the progression of the cell cycle during the mitotic phase, SPAG5 
dysregulation could contribute to chromosome instability and aneuploidy, both of 
which are hallmarks of malignant cells and could confer vulnerability on the cancer 
cell. Given that drugs such as the anthracyclines and taxane, which interfere with the 
normal progression of mitosis, belong to the most successful chemotherapeutic 
compounds that are currently used for anti-cancer treatment, SPAG5 could be a 
molecular target on which the development of “next generation anti-mitotic drugs” 
could be based.  Recent studies in cervical cancer 34, 35 reported SPAG5 to be up-
regulated, and demonstrated that the down-regulation of SPAG5 inhibited cell 
proliferation/growth, increased apoptosis and hindered cell migration and invasion. 35 
Furthermore, it is possible that “anti-SPAG5 agents” could sensitize resistant BC 
cells to current treatment regimens.   
The potential clinical significance of our results primarily relates to the identification 
of BC patients who are likely to benefit from anthracycline-based chemotherapy. 
Validating our results in a randomized-prospective Neo-ACT trial would allow 
patients whose tumour response would be poor to be spared from enduring the 
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unnecessary risk of cardiac toxicity, when other more effective agents can be used. 
Although the mechanism linking SPAG5+ and response to anthracycline is unknown 
and further investigation is warranted, it could be due to the accumulation of DNA 
damage, abnormal mitoses, and subsequent mitotic catastrophe.36  
In summary, our findings have the potential to introduce an accurate predictive 
biomarker for chemotherapy response, which would facilitate the effective tailoring of 
BC treatment. This work may lead to the development of novel therapeutic strategies 
for treating a subtype of BC, thereby increasing the chance of cure from BC.  
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AC = anthracycline combination 
AC-ACT = anthracycline combination adjuvant chemotherapy 
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AR = androgen receptor 
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HER2 = human epidermal growth factor receptor 2 
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NPI = Nottingham prognostic index 
NT = Nottingham series 
pCR = pathological complete response 
PR = progesterone receptor 
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TNBC = triple negative breast cancer 
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Tables 
Table-1: Multivariable Cox regression models analysis in different breast cancer 
cohorts. 
 
A. Multivariable Cox regression model analysis for breast cancer specific survival 
in the Uppsala test cohort (SPAG5 transcript) (n=249) 
Variables HR 95·0% CI P value 
Lower Upper 
SPAG5 mRNA (high) 1·62 1·03 2·53 0·036* 
MKI67 mRNA (high) 0.991 0.486 1.71 0·77 
Lymph node status (positive) 1·61 1·01 2·57 0·050* 
96-gene genomic grade index (GGI) 26 
 
G1 
G2a 
G2b 
G3 
 
 
1 
0·94 
1·77 
1·73 
 
 
 
0·50 
0·82 
0·76 
 
 
 
1·79 
3·96 
3·97 
0·34 
Age at diagnosis** 1·01 0·99 1·03 0·16 
Tumour size (continuous) (mm) 1·09 0·95 1·24 0·21 
Oestrogen receptor (positive) 1·43 0·76 2·71 0·27 
TP53 mutation 1·07 0·62 1·86 0·80 
B. Multivariable Cox regression model (1) analysis for breast cancer specific 
survival in the METABRIC cohort (SPAG5 transcript) (n=1980) 
SPAG5 mRNA (high) 1·27 1·02 1·58 0·034* 
Lymph node (LN) stage 
Negative 
1-3 positive LNs 
>3 positive LNs 
 
1·00 
1·68 
3·42 
 
 
1·31 
2·59 
 
 
2·16 
4.52 
<0·0001* 
Histologic grade 
Low 
Intermediate 
High 
 
1·00 
1·79 
2·05 
 
 
1·08 
1·23 
 
 
2·95 
3·39 
0·017* 
Size 1·01 1.007 1·015 <0·0001* 
Age at diagnosis** 1·01 1·002 1·02 0·015* 
HER2 1·50 1·18 1·91 0·0010*  
Progesterone receptor (positive) 0·77 0·62 0·96 0·020* 
Oestrogen receptor (positive) 1·06 0·78 1·45 0·70 
Hormone therapy 1·23 0·82 1·02 0·12 
Chemotherapy 1·31 0·96 1·78 0·090 
Hormone therapy*SPAG5 0·62 0·41 0·93 0·021* 
Chemotherapy*SPAG5 0·84 0·55 1·28 0·42 
C. Multivariable Cox regression model (2) analysis for breast cancer specific 
survival in the METABRIC cohort (SPAG5 transcript) (n=1980) 
SPAG5 mRNA (high) 1·31 1·04 1·65 0·020* 
PAM-50 Molecular subclasses 28 
PAM50-LumA 
PAM50-LumB 
 
1 
2·13 
 
 
1·62 
 
 
2·80 
<0·0001* 
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PAM50-HER2 
PAM50-Basallike 
PAM50-Normal 
2·34 
1·89 
1·45 
1·72 
1·38 
1·01 
3·18 
2·59 
2·08 
Hormone therapy 1·31 1·06 1·60 0·010* 
Chemotherapy 1·31 1·66 2·59 <0·0001* 
Hormone therapy*SPAG5 0·57 0·38 0·84 0·0050* 
Chemotherapy*SPAG5 1·18 0·78 1·78 0·43 
D. Multivariable Cox regression model (3) analysis for breast cancer specific 
survival in METABRIC cohort (SPAG5 transcript) (n=1980) 
SPAG5 mRNA (high) 1·33 1·06 1·67 0·014* 
Integrated Clusters (IntClust)11 
intClust.1 
intClust.2  
intClust.3  
intClust.4  
intClust.5  
intClust.6  
intClust.7  
intClust.8  
intClust.9  
intClust.10 
 
1 
1·47 
0·38 
0·69 
1·58 
1·13 
0·58 
0·65 
1·08 
0·75 
 
 
0·92 
0·24 
0·46 
1·09 
0·70 
0·37 
0·44 
0·72 
0·50 
 
 
2·34 
0·61 
1·03 
2·30 
1·81 
0·93 
0·97 
1·63 
1·13 
<0·0001* 
Hormone therapy 1·23 1·003 1·50 0·047* 
Chemotherapy 2·02 1·62 2·51 <0·0001* 
Hormone therapy*SPAG5 0·53 0·36 0·77 0·020* 
Chemotherapy*SPAG5 1·18 0·78 1·78 0·66 
E. Multivariable Cox regression analysis of SPAG5 transcript in untreated Lymph 
node negative “Desmedt cohort” 
SPAG5 mRNA (high) 2·34 1·24 4·42 0·0090* 
Oestrogen receptor (positive) 0·67 0·38 1·22 0·19 
NPI 1·74 0·712 4·23 0·22 
Adjuvant-online (AOL) 0·76 0·30 1·94 0·56 
76-gene prognostic signature (Veridex) 13 1·52 0·75 3·06 0·24 
F. Multivariable Cox regression analysis of SPAG5 protein for breast cancer-
specific survival at 20 years follow-up in Nottingham historical early stage 
breast cancer cohort (n=1650) 
SPAG5 protein expression (positive) 1·73 1·23 2·46 0·0020* 
Tumour size (continuous) (mm) 1·18 1·07 1·31 0·0010* 
Lymph node (LN) status  
Negative  
Positive 
 
1 
1·95 
 
 
1·51 
 
 
2·52 
<0.0001* 
Histological grade  
Low/intermediate  
High 
 
1 
1·83 
 
 
1·33 
 
 
2·50 
0·00020* 
Oestrogen receptor (positive) 1·20 0·82 1·74 0·350 
HER2 overexpression (positive) 1·60 1·16 2·52 0·0040* 
Progesterone receptor status (positive) 0·66 0·47 0·92 0·015* 
Ki67 (positive) 1·44 1·03 2·01 0·034* 
Chemotherapy status (CMF) 1·55 1·13 2·17 0·010* 
Hormone therapy (yes) 1·31 0·99 1·73 0·059 
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Chemotherapy*SPAG5 1·65 0·85 3·23 0·14 
Hormone therapy *SPAG5 1·95 1·14 3·35 0·015* 
G.  Multivariable Cox regression analysis of SPAG5 protein for breast cancer-
specific survival at 10 years follow-up in Nottingham early stage oestrogen 
receptor negative breast cancer cases (n=697) 
Model without interaction terms 
SPAG5 protein expression (positive) 0·68 0·50 0·92 0·013* 
Tumour size (continuous) 1·06 1·02 1·09 0·0010* 
Lymph node (LN) status  
Negative  
Positive 
 
1 
2·60 
 
 
1·92 
 
 
3·50 
<0·0001* 
Histological grade  
Low/intermediate  
High 
 
1 
1·67 
 
 
0·98 
 
 
2·86 
0·059 
Menopausal status (post vs pre) 1·34 0·99 1·82 0·060 
HER2 overexpression (positive) 0·92 0·64 1·31 0·64 
Bcl2 (positive) 0·60 0·40 0·90 0·013* 
Chemotherapy status  
 
No Chemotherapy  
CMF  
Anthracycline 
 
 
1 
0·80 
0·61 
 
 
 
0·54 
0·42 
 
 
 
1·18 
0·89 
 
 
 
0·260 
0·010* 
Model with interaction terms 
SPAG5 protein expression (positive) 0·48 0·30 0·76 0·0020* 
Tumour size (continuous) 1·05 1·02 1·09 0·0030* 
Lymph node (LN) status  
Negative  
Positive 
 
1 
2·57 
 
 
1·90 
 
 
3·46 
<0.0001* 
Histological grade  
Low/intermediate  
High 
 
1 
1·65 
 
 
0·97 
 
 
2·82 
0·066 
Menopausal status (post vs pre) 1·35 0·99 1·84 0·056 
HER2 overexpression (positive) 0·93 0·65 1·34 0·70 
Bcl2 (positive) 0·63 0·42 0·94 0·023 
Chemotherapy status  
No Chemotherapy  
CMF  
Anthracycline 
 
1 
0·79 
0·59 
 
 
0·54 
0·40 
 
 
1·16 
0·87 
 
 
0·23 
0·008* 
SPAG5*CMF interaction term 0·70 0·32 1·50 0·36 
SPAG5*Anthracycline interaction term 0·43 0·20 0·93 0·032* 
H. Multivariable Cox regression analysis for clinical outcome (distant relapse-free 
survival (DRFS)) in the University of Texas MD Anderson Cancer Centre 
Taxane/Anthracycline based neo-adjuvant cohort (n=508) 
SPAG5 transcript expression (positive) 0·68 0·48 0·97 0·031* 
Chemo-sensitivity prediction signature 19 
Low vs high 
 
0·49 
 
0·36 
 
0·67 <0.0001* 
96- gene genomic grade index (GG1) 26 
Grade 1/Grade2a vs Grade 2b/Grade 3-like 0·646 0·323 1·29 0·21 
30-gene (DLDA30)27 2·09 0·95 4.56 0·065 
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Low vs High 
PAM-50 Molecular subclasses 28 
PAM50-LumA vs others 
PAM50-LumB vs others 
PAM50-HER2 vs others 
PAM50-Basal-like vs others 
 
0·16 
0·24 
0·14 
0·28 
 
0·04 
0·07 
0·03 
0·07 
 
0·58 
0·88 
0·66 
1·10 
0·042* 
0·0060* 
0·031* 
0·013* 
0·068 
Clinical AJCC stage 
I/II vs III 
 
2·03 
 
1·38 
 
2·99 
 
0·00040* 
MKI67 transcript 1·22 0·71 2·07 0·47 
 
*Statistically significant at p<0·05. 
**Age was a continuous value with increments of 5 years. 
SPAG5; Sperm-associated antigen, ER; Oestrogen receptor; HER2; Human 
epidermal growth factor receptor 2, Bcl2;  B-cell CLL/lymphoma 2; GG;I genomic 
grade index, IntClust; Integrated Clusters; DLDA: diagonal linear discrimination 
analysis, AJCC; American Joint Committee of Cancer.   
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Table-2: Multivariable logistic regression models analysis for pathological complete 
response (pCR) or residual cancer burden (RCB) in neo-adjuvant.  
 
A. Multivariable logistic regression models analysis for pathological 
complete response (pCR) in the Nottingham anthracycline-based neo-
adjuvant BC cohort (SPAG5 protein expression) 
Variables OR 
95.0% CI 
P value 
Lower Upper 
SPAG5 protein expression (+) 8·75 2·42 31·62 0·0010* 
Ki67 protein expression (+) 2·81 0·77 10·24 0·11 
Bcl2 protein expression (+) 0·19 0.05 0·69 0·010* 
TOP2A protein expression (+) 3·81 0·98 14·73 0·053 
ER protein expression (+) 0·77 0·42 2·84 0·25 
HER2 expression (+) 0·84 0·23 3·12 0·79 
Taxane (+) 0·67 0·21 2·21 0·52 
Age (continuous)** 1·04 0·98 1·10 0·25 
AJCC stage (i/II us III/IV) 0.35 0·109 1·52 0·084 
Histological Grade (G1/2 vs G3) 0·417 0·11 1·54 0·18 
B. Multivariable logistic regression models analysis for pathological 
complete response (pCR) in the University of Texas MD Anderson 
Cancer Centre Taxane/Anthracycline-based neo-adjuvant cohort 
SPAG5 transcript) (+) 1·71  1·07 2·74 0·024* 
Pathological Complete response 
(pCR) prediction signature  
Low vs high 
 
 
1·17 
 
 
0·44 
 
 
3·10 
0·75 
96- gene genomic grade index (GGI) 
26 
Grade 1/Grade2 a vs Grade 2 b/Grade 
3-like 
0·26 0·09 0·78 0·016* 
30-gene (DLDA30) 27 
Low vs High 
1·17 0·44 3·10 0·75 
PAM-50 Molecular subclasses 28 
PAM50-LumA vs others 
PAM50-LumB vs others 
PAM50-HER2 vs others 
PAM50-Basal-like vs o 
 
0·16 
0·24 
0·14 
0·28 
 
0·04 
0·07 
0·03 
0·07 
 
0·58 
0·88 
0·66 
1·10 
0·042* 
0·0060* 
0·031 * 
0·013 * 
0·068 
Clinical AJCC stage I/II vs III 0.31 0.76 0·45 0·012* 
Histological grade G1/G2 vs G3 2·37 1·15 4·89 0·020* 
Age of patients (continuous) 0·99 0·96 1·01 0·26 
Oestrogen receptor status (+) 0·46 0·21 1·04 0·063 
Progesterone receptor  (+) 1·09 0·86 1·39 0·47 
C. Multivariable logistic regression models analysis for residual cancer 
burden (RCB) in neo-adjuvant cohorts in Multicentre phase II neo-
adjuvant clinical trial cohort (NCT00455533; n=253) 
SPAG5 transcript) (+) 1·80  1·02 3·02 0·044* 
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Oestrogen receptor status (+) 0·59 0·25 1·36 0·21 
Progesterone receptor  (+) 0·41 0·02 1·02 0·042* 
HER2 (+) 0·96 0·36 2·62 0·94 
Age (≥50 years) 0·40  0·22 0·73 0·0030* 
Size( ≥5cm) 0·59  0·32 1·09 0·090 
 
*Statistically significant at p<0·05 
**Age was a continuous value with increments of 1 years. 
 
SPAG5; Sperm-associated antigen, ER; Oestrogen receptor; HER2; Human 
epidermal growth factor receptor 2, TOP2A; Topoisomerase II alpha, Bcl2;  B-cell 
CLL/lymphoma 2; GG;I genomic grade index, IntClust; Integrated Clusters; DLDA: 
diagonal linear discrimination analysis, AJCC; American Joint Committee of Cancer 
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Figure legends 
Figure 1: Concept diagram presenting each of the patient cohorts along with a 
summary of the hypotheses and methodology applied to each.  
Figure 2 (A-F): Clinical outcome of SPAG5-gene-gain/amplification and 
transcript in the METABRIC cohort. Kaplan-Meier curves showing the relationship 
between SPAG5-gene-gain/amplification and breast cancer-specific survival (BCSS) 
in all patients (A), oestrogen receptor positive (ER-positive) (B), and ER- negative 
subgroups (C). Kaplan-Meier curves are showing the relationship between SPAG5-
transcript expression and BCSS in all patients (D), oestrogen receptor positive (ER-
positive) (E), ER- negative (F). (G-I): Relationship between SPAG5 transcript 
expression and clinical outcome in untreated lymph node negative breast cancer 
(BC) cohorts.  Kaplan-Meier curves showing the relationship between SPAG5-
transcript expression and: relapse in Wang et al cohort (G), distant relapse in 
Schmidt et al (H), and death from BC in Desmedt et al cohort (I). See text for details.   
(Homo; loss of both gene alleles, hetero; loss of one copy of the gene), Neu; 2 
copies of the gene, Gain; >2 copies of the gene but <6 copies and Amp; 
amplification ≥6 copy of the gene)    
Figure 3 (A-C): Relationship between SPAG5-protein expression and clinical 
outcome in a large, well-characterized cohort of Nottingham Historical Early 
Stage BC cohort (n=1650). Kaplan-Meier curves showing the relationship between 
SPAG5-protein expression and breast cancer-specific survival (BCSS) in all patients 
(G), oestrogen receptor positive (ER-positive) (H) and ER- negative subgroups.   
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Figure 3 (D-F): Clinical outcome of ER-negative breast cancer stratified 
according to SPAG5-protein expression and adjuvant chemotherapy treatment 
status. Kaplan-Meier curves showing the relationship between SPAG5-protein 
expression and breast cancer specific survival (BCSS) in all ER- cohort cases (D).  
E-F: Kaplan-Meier curves showing the relationship between the adjuvant 
chemotherapy protocols (no chemotherapy (No-CT), CMF (cyclophosphamide, 
Methotrexate and 5-Flourouracil) and anthracycline combination therapy) and BCSS 
in low SPAG5-protein expression (-) (E), and high SPAG5-protein expression (+) (F). 
See text for details.  
Supplementary figure legends: 
Supplementary-Fig.S1: Concept diagram summarizing the artificial neural network 
analysis methodology. 
Supplementary-Fig.S2 (A-B): Representative photomicrographs showing 
SPAG5-protein expression in breast cancer tissue. (A) Low SPAG5-protein 
expression (-) and (B) high Spag5-protein expression (+) in neoplastic cells 
(magnification x 200)  
Supplementary-Fig.S3: Gene interaction maps. Visualization of the top 100 
interactions of the common proliferation genes in the Nottingham discovery cohort, 
showing SPAG5 as a central hub(Cystoscope software). . 
Supplementary-Fig.S4: Gene interaction maps. Visualization of the interaction 
map of proliferation related factor KIF2C where SPAG5 again holds a prominent 
position (Cystoscope software). 
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Supplementary-Fig.5 (A-F):  SPAG5-gene copy number aberrations (CNA), as 
determined by SNP analysis in the METABRIC cohort. The SPAG5-gene-CNA in 
different histological grades (A), PAM50 molecular breast cancer subtypes: Basal-
like (Basal), HER2-enrich (HER2+), luminal A (LumA), Luminal B (LumB) and normal 
breast like (Normal). (B). Box-and-Whisker plots demonstrating the correlation 
between SPAG5 transcript expression and both its CNA (C), ER expression (D), 
molecular subclasses (E), and grade (F). (G-H): The relationship between 
integrative-clusters (Int-Clust1-10) and SPAG5 CNAs (G) and transcript (H). 
Supplementary-Fig.6 (A-F): Clinical outcome of SPAG5 transcript in the 
METABRIC cohort. Kaplan-Meier curves showing the relationship between SPAG5-
transcript and breast cancer-specific survival (BCSS) in low risk BC [Nottingham 
Prognostic index (NPI)<3·4] (A), lymph node negative (B), and lymph node positive 
(C) subgroups.   
Supplementary-Fig.7 (A-E): Relationship between SPAG5 transcript levels and 
clinical outcome in the combined multicentre cohort (MCC, n=5439). The forest 
plot showing the impact of SPAG5 transcript on survival in terms of hazard ratio (HR) 
and a confidence interval (CI) in different cohorts all at once provides a better 
(visual) insight into the variability of results between studies (A). Kaplan-Meier 
curves showing the relationship between SPAG5-transcript expression and the risk 
of relapse or death from breast cancer in oestrogen receptor positive (ER-positive) 
(B), ER- negative subgroups (C), lymph node negative (D), and lymph node positive 
(E).  
Supplementary-Fig.8 (A-C): Clinical outcome of SPAG5 protein in the 
Nottingham historical early stage breast cancer cohort. Kaplan-Meier curves 
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showing the relationship between SPAG5-transcript and breast cancer-specific 
survival (BCSS) in low risk BC [Nottingham Prognostic index (NPI)<3·4] (A), lymph 
node negative (B), and lymph node positive (C) subgroups.   
Supplementary-Fig.9 (A-E): Clinical outcome of Nottingham early stage ER-
negative breast cancer stratified according to SPAG5-protein expression and 
adjuvant chemotherapy treatment status. Kaplan-Meier curves showing the 
relationship between SPAG5-protein expression and breast cancer specific survival 
(BCSS) in: chemotherapy naïve patients (A), chemotherapy treated cohort (B), 
anthracycline naïve patients (C), and anthracycline treated cohort (D).   
Supplementary-Fig.10 (A-E): The relationships between SPAG5-protein and 
SPAG5-transcript expression and pathological complete response (pCR) rate 
and clinical outcome following anthracycline combined neo-adjuvant 
chemotherapy (AC-Neo-ACT) treatment with or without taxane.  Relationship 
between SPAG5-protein expression and pCR rate in the Nottingham Anthracycline-
based neo-adjuvant BC cohort (A). Kaplan-Meier curves illustrating the relationship 
between the expression of SPAG5-protein expression in core biopsies prior to 
chemotherapy (B) and in surgically removed residual tumour after chemotherapy, 
with breast cancer specific survival (BCSS) (C), see text for details.  (D-E): Kaplan-
Meier curves illustrating the relationship between the expression level of SPAG5-
transcript and distant relapse free survival (DRFS), in all cases (D) and in non-
pathological response cases with residual disease (E).  
 
